
MBX Biosciences, Inc. (NASDAQ:MBX – Free Report) – Research analysts at HC Wainwright issued their FY2026 earnings per share estimates for MBX Biosciences in a report released on Thursday, November 12th. HC Wainwright analyst M. Kapoor anticipates that the company will earn ($3.13) per share for the year. HC Wainwright has a “Buy” rating and a $90.00 price objective on the stock. The consensus estimate for MBX Biosciences’ current full-year earnings is ($3.42) per share. HC Wainwright also issued estimates for MBX Biosciences’ Q4 2026 earnings at ($1.00) EPS, Q1 2027 earnings at ($1.01) EPS, Q2 2027 earnings at ($1.08) EPS, Q3 2027 earnings at ($1.12) EPS, Q4 2027 earnings at ($1.16) EPS and FY2027 earnings at ($4.37) EPS.
MBX has been the topic of several other reports. Mizuho raised their price objective on MBX Biosciences from $57.00 to $91.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Guggenheim boosted their target price on shares of MBX Biosciences from $88.00 to $150.00 and gave the company a “buy” rating in a research note on Friday, October 2nd. Stifel Nicolaus increased their target price on shares of MBX Biosciences from $70.00 to $84.00 and gave the stock a “buy” rating in a report on Monday, October 12th. Wall Street Zen downgraded shares of MBX Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MBX Biosciences in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $87.30.
MBX Biosciences Stock Performance
Shares of NASDAQ MBX opened at $55.94 on Monday. The company has a market capitalization of $2.78 billion, a price-to-earnings ratio of -18.22 and a beta of 0.18. MBX Biosciences has a twelve month low of $23.07 and a twelve month high of $72.64. The business has a 50 day simple moving average of $55.78 and a 200-day simple moving average of $46.39.
MBX Biosciences (NASDAQ:MBX – Get Free Report) last issued its earnings results on Monday, November 9th. The company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.49).
Insider Activity
In related news, CEO Steven Hoerter sold 4,893 shares of the business’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $54.82, for a total transaction of $268,234.26. Following the completion of the transaction, the chief executive officer owned 78,045 shares in the company, valued at $4,278,426.90. The trade was a 5.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 31.09% of the company’s stock.
Institutional Investors Weigh In On MBX Biosciences
Several large investors have recently added to or reduced their stakes in MBX. State of Wyoming bought a new stake in MBX Biosciences in the second quarter valued at $58,000. Sterling Capital Management LLC boosted its holdings in shares of MBX Biosciences by 847.7% during the third quarter. Sterling Capital Management LLC now owns 1,033 shares of the company’s stock valued at $61,000 after acquiring an additional 924 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of MBX Biosciences during the third quarter valued at $144,000. Quantbot Technologies LP bought a new position in shares of MBX Biosciences during the second quarter worth about $213,000. Finally, Sei Investments Co. grew its position in shares of MBX Biosciences by 17.4% during the first quarter. Sei Investments Co. now owns 8,989 shares of the company’s stock worth $268,000 after acquiring an additional 1,332 shares during the last quarter.
Recent MBX Biosciences Headlines
Investors following MBX have been watching these headlines:
- Positive Sentiment: Oppenheimer initiated or reiterated a Buy rating on MBX, adding to favorable analyst sentiment. Oppenheimer Buy rating
- Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $90 price target, implying substantial upside from the roughly $56 share price cited in the coverage report. Citizens also reiterated its Market Outperform rating. HC Wainwright coverage Citizens rating
- Neutral Sentiment: CEO Steven Hoerter sold 4,893 shares for about $268,000, but the filing said the sale covered tax withholding on vested equity awards. He retained 78,045 shares, making the transaction less concerning than a discretionary sale. CEO share sale
MBX Biosciences Company Profile
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for endocrine and metabolic disorders. The company’s research focuses on conditions in which naturally occurring hormones are deficient or do not function adequately. MBX uses its Precision Endocrine Peptide (PEP) platform to design peptide medicines intended to provide more durable hormone activity. Its lead candidate, MBX 2109, is being developed as a long-acting parathyroid hormone replacement therapy for people with chronic hypoparathyroidism.
Read More
- Five stocks we like better than MBX Biosciences
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for MBX Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MBX Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
